Cargando…

SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far

Respiratory infections are the most common and most frequent diseases, especially in children and the elderly, characterized by a clear seasonality and with an incidence that usually tends to decrease with increasing age. These infections often resolve spontaneously, usually without the need for ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Biondo, Carmelo, Midiri, Angelina, Gerace, Elisabetta, Zummo, Sebastiana, Mancuso, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786139/
https://www.ncbi.nlm.nih.gov/pubmed/36556452
http://dx.doi.org/10.3390/life12122087
_version_ 1784858219686920192
author Biondo, Carmelo
Midiri, Angelina
Gerace, Elisabetta
Zummo, Sebastiana
Mancuso, Giuseppe
author_facet Biondo, Carmelo
Midiri, Angelina
Gerace, Elisabetta
Zummo, Sebastiana
Mancuso, Giuseppe
author_sort Biondo, Carmelo
collection PubMed
description Respiratory infections are the most common and most frequent diseases, especially in children and the elderly, characterized by a clear seasonality and with an incidence that usually tends to decrease with increasing age. These infections often resolve spontaneously, usually without the need for antibiotic treatment and/or with the possible use of symptomatic treatments aimed at reducing overproduction of mucus and decreasing coughing. However, when these infections occur in patients with weakened immune systems and/or underlying health conditions, their impact can become dramatic and in some cases life threatening. The rapid worldwide spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has caused concern for everyone, becoming especially important for individuals with underlying lung diseases, such as CF patients, who have always paid close attention to implementing protective strategies to avoid infection. However, adult and pediatric CF patients contract coronavirus infection like everyone else. In addition, although numerous studies were published during the first wave of the pandemic on the risk for patients with cystic fibrosis (CF) to develop severe manifestations when infected with SARS-CoV-2, to date, a high risk has been found only for patients with poorer lung function and post-transplant status. In terms of preventive measures, vaccination remains key. The best protection for these patients is to strengthen preventive measures, such as social distancing and the use of masks. In this review, we aim to summarize and discuss recent advances in understanding the susceptibility of CF individuals to SARS-CoV-2 infection.
format Online
Article
Text
id pubmed-9786139
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97861392022-12-24 SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far Biondo, Carmelo Midiri, Angelina Gerace, Elisabetta Zummo, Sebastiana Mancuso, Giuseppe Life (Basel) Review Respiratory infections are the most common and most frequent diseases, especially in children and the elderly, characterized by a clear seasonality and with an incidence that usually tends to decrease with increasing age. These infections often resolve spontaneously, usually without the need for antibiotic treatment and/or with the possible use of symptomatic treatments aimed at reducing overproduction of mucus and decreasing coughing. However, when these infections occur in patients with weakened immune systems and/or underlying health conditions, their impact can become dramatic and in some cases life threatening. The rapid worldwide spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has caused concern for everyone, becoming especially important for individuals with underlying lung diseases, such as CF patients, who have always paid close attention to implementing protective strategies to avoid infection. However, adult and pediatric CF patients contract coronavirus infection like everyone else. In addition, although numerous studies were published during the first wave of the pandemic on the risk for patients with cystic fibrosis (CF) to develop severe manifestations when infected with SARS-CoV-2, to date, a high risk has been found only for patients with poorer lung function and post-transplant status. In terms of preventive measures, vaccination remains key. The best protection for these patients is to strengthen preventive measures, such as social distancing and the use of masks. In this review, we aim to summarize and discuss recent advances in understanding the susceptibility of CF individuals to SARS-CoV-2 infection. MDPI 2022-12-13 /pmc/articles/PMC9786139/ /pubmed/36556452 http://dx.doi.org/10.3390/life12122087 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Biondo, Carmelo
Midiri, Angelina
Gerace, Elisabetta
Zummo, Sebastiana
Mancuso, Giuseppe
SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
title SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
title_full SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
title_fullStr SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
title_full_unstemmed SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
title_short SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
title_sort sars-cov-2 infection in patients with cystic fibrosis: what we know so far
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786139/
https://www.ncbi.nlm.nih.gov/pubmed/36556452
http://dx.doi.org/10.3390/life12122087
work_keys_str_mv AT biondocarmelo sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar
AT midiriangelina sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar
AT geraceelisabetta sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar
AT zummosebastiana sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar
AT mancusogiuseppe sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar